scholarly journals Systemic anaplastic large cell lymphoma in a child presenting with bone marrow involvement and clinical features of acute leukaemia

2002 ◽  
Vol 69 (2) ◽  
pp. 150-151 ◽  
Author(s):  
Sumeet Gujral ◽  
Ranjan Prasad ◽  
K.N. Naresh
Keyword(s):  
Bone Marrow ◽  
Clinical Features ◽  
Anaplastic Large Cell Lymphoma ◽  
Acute Leukaemia ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Large Cell Lymphoma

Proliferation of B lymphocytes that preceded the bone marrow involvement of anaplastic large-cell lymphoma

2009 ◽  
Vol 52 (2) ◽  
pp. 119-123
Author(s):  
Hiroshi Kojima ◽  
Toshitaka Kobayashi ◽  
Shyoichi Mitsuhashi ◽  
Yuji Sato ◽  
Toshiro Nagasawa ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Lymphocytes ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Large Cell Lymphoma

scholarly journals Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma

Leukemia ◽  
2005 ◽  
Vol 19 (9) ◽  
pp. 1643-1647 ◽  
Author(s):  
L Mussolin ◽  
M Pillon ◽  
E S d'Amore ◽  
N Santoro ◽  
A Lombardi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Clinical Implications ◽  
Large Cell Lymphoma

scholarly journals Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement

2018 ◽  
Author(s):  
Sanam Loghavi ◽  
L Jeffrey Medeiros ◽  
Sanaz Javadi ◽  
Pei Lin ◽  
Joseph D Khoury ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Breast Implant ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Large Cell Lymphoma

Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse.

1991 ◽  
Vol 9 (2) ◽  
pp. 236-242 ◽  
Author(s):  
L E Robertson ◽  
J R Redman ◽  
J J Butler ◽  
B M Osborne ◽  
W S Velasquez ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Lymph Node Biopsy ◽  
High Rate ◽  
Late Relapse ◽  
Diffuse Large Cell Lymphoma ◽  
Large Cell Lymphoma ◽  
Risk Of Relapse

From 1975 to 1988, 50 patients with lymph node biopsy-documented diffuse large-cell lymphoma (DLCL) presented with bone marrow involvement. Twenty-four patients (48%) had large-cell lymphoma (LCL) in the bone marrow and were compared with 19 (38%) patients who had small cleaved-cell lymphoma (SCCL) in the marrow. Additionally, seven patients (14%) had mixed small- and large-cell lymphoma (ML) in the marrow. Patients who had LCL marrow involvement were younger (P less than .02) and more frequently had elevated lactic dehydrogenase (LDH) levels (P less than .001), high tumor burden (P less than .01), and more sites of extranodal disease (P less than .05) than those with SCCL in the marrow. The complete response (CR) rate to multiagent chemotherapy was 16.7% in the LCL group and 89.4% in the SCCL group (P less than .001). One third of the patients with LCL in the marrow developed CNS involvement, compared with only one patient in the SCCL group (P = .06). Overall 5-year survival was 79% in patients with SCCL marrow involvement, compared with only 12% in patients with LCL in the marrow (P = .002). Despite a high CR rate, patients with marrow involved by SCCL were at a high continuous risk of relapse with only a 30% failure-free survival at 5 years. We conclude that bone marrow involvement with LCL predicts for extremely poor prognosis with low response rate and short survival. Patients with SCCL in the bone marrow have a high rate of CR and a high rate of 5-year survival; however, there is a high risk of late relapse, and only 15% are in a continuous remission at 8 years.

Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features

Blood ◽  
1999 ◽  
Vol 93 (7) ◽  
pp. 2202-2207 ◽  
Author(s):  
J. Rodriguez ◽  
P. McLaughlin ◽  
F.B. Hagemeister ◽  
L. Fayad ◽  
M.A. Rodriguez ◽  
...  
Keyword(s):  
Clinical Features ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
Large Cell ◽  
Score System ◽  
Prognostic Features ◽  
Aggressive Lymphomas ◽  
Large Cell Lymphoma

Abstract It is debated whether follicular large cell lymphoma (FLCL) has a clinical behavior that is distinct from indolent follicular lymphomas, and whether there is a subset of patients who can be potentially cured. We report here our experience with 100 FLCL patients treated at our institution since 1984 with three successive programs. We evaluated the predictive value of pretreatment clinical features, including two risk models, the Tumor Score System and the International Prognostic Index (IPI). With a median follow-up of 67 months, the 5-year survival is 72% and the failure-free survival (FFS) is 67%, with a possible plateau in the FFS curve, particularly for patients with stage I-III disease. Features associated with shorter survival included age ≥60, elevated lactic dehydrogenase (LDH) or beta-2-microglobulin (β2M), advanced stage, and bone marrow involvement. Stage III patients had significantly better survival than stage IV patients (P < .05). By the IPI and Tumor Score System, 80% of the patients were in the lower risk groups; both systems stratified patients into prognostic groups. Patients with FLCL have clinical features and response to treatment similar to that reported for diffuse large cell lymphoma. Prognostic risk systems for aggressive lymphomas are useful for FLCL. A meaningful fraction of patients may possibly be cured when treated as aggressive lymphomas.

scholarly journals Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma

2003 ◽  
Vol 14 (2) ◽  
pp. 273-276 ◽  
Author(s):  
J.K. Campbell ◽  
J.P. Matthews ◽  
J.F. Seymour ◽  
M.M. Wolf ◽  
S.K. Juneja
Keyword(s):  
Bone Marrow ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Diffuse Large Cell Lymphoma ◽  
Large Cell Lymphoma

scholarly journals TRAF1-ALK fusion indicates poor prognosis to ALK tyrosine kinase inhibitors in relapsed/refractory ALK-positive anaplastic large-cell lymphoma patients

2020 ◽  
Author(s):  
Diwen Pang ◽  
Ling Huang ◽  
Xinmiao Jiang ◽  
Feili Chen ◽  
Hanguo Guo ◽  
...  
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Bone Marrow Involvement ◽  
Large Cell ◽  
Fusion Partner ◽  
Alk Inhibitors ◽  
Anaplastic Lymphoma ◽  
Large Cell Lymphoma ◽  
Alk Positive

Abstract Background Relapsed/refractory (R/R) anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) respond to ALK inhibitors, but resistance bears a poor prognosis. No biomarkers predict a long duration of response to ALK inhibitors. The ALK gene was first identified as the fusion partner of the nucleophosmin (NPM1) gene in recurrent t(2;5)(p23;q35) found in an ALCL subset. However, several distinct ALK fusions that result in highly different characteristics have also been described in lymphomas. Methods We retrospectively reviewed 43 patients with pathologically confirmed ALK-positive ALCL at Guangdong Provincial People’s Hospital from February 2007 through February 2020, including seven R/R patients who received ALK inhibitors (six with crizotinib and one with alectinib). We performed next-generation sequencing (NGS) with paraffin-embedded tissue for these seven R/R patients and one patient with a peripheral blood sample. We evaluated clinical characteristics and survival status. Results The median age of all patients was 29 (range 15–66) years. Most patients were male with advanced stage and B symptoms. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 60% and 70%, respectively with a median follow-up of 52.2 (range 2.4–168.6) months. Multivariate analyses revealed that only bone marrow involvement was an independent prognostic factor for PFS (P = 0.03) and OS (P = 0.03). Of the seven R/R patients, the median line number of therapies was four (range 3–7) and that of ALK inhibitor usage was three (range 2–5). The overall response rate was 100% (n = 7). The NGS identified four patients with the NPM1-ALK fusion and two with tumor necrosis factor receptor-associated factor 1 gene (TRAF1)-ALK fusion; the latter quickly developed resistance to chemotherapy and ALK inhibitors. Conclusions ALK inhibitors improved survival of patients with R/R ALK-positive ALCLs. TRAF1-ALK fusion may predict a poor clinical outcome to chemotherapy and ALK inhibitors. This ALK fusion may reflect a trend toward the aggressive behavior of lymphomas.

Sign in / Sign up

Export Citation Format

Share Document